Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)
India · Delayed Price · Currency is INR 164.19
+12.08 (7.94%)
Jun 1, 2026, 3:30 PM IST
Ind-Swift Laboratories Revenue
In the fiscal year ending March 31, 2026, Ind-Swift Laboratories had annual revenue of 6.88B INR with 22.53% growth. Ind-Swift Laboratories had revenue of 1.72B in the quarter ending March 31, 2026, a decrease of -66.14%.
Revenue
6.88B
Revenue Growth
+22.53%
P/S Ratio
1.92
Revenue / Employee
5.52M
Employees
1,246
Market Cap
13.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.88B | 1.27B | 22.53% |
| Mar 31, 2025 | 5.62B | -11.47B | -67.13% |
| Mar 31, 2024 | 17.09B | 4.93B | 40.56% |
| Mar 31, 2023 | 12.16B | 1.63B | 15.48% |
| Mar 31, 2022 | 10.53B | 1.46B | 16.12% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.45B |
| Innova Captab | 16.30B |
| Solara Active Pharma Sciences | 13.75B |
| Windlas Biotech | 9.04B |
| Orchid Pharma | 8.47B |
| RPG Life Sciences | 7.08B |
| Sigachi Industries | 4.85B |
| Beta Drugs | 3.85B |
Ind-Swift Laboratories News
- 3 months ago - Ind-Swift Laboratories steps up export push with Rs 40 crore Jammu facility upgrade - Business Upturn